Articles
To build or buy? Examining the pros of building vs. buying a biorepository facility
Biopharma companies face a critical decision: should they invest in building an in-house biorepository or partner with an external provider for their storage and management needs? Each approach has its benefits, from full control and customization to cost savings and scalability.
Partnership-driven value in drug development: Compelling insights from new research
Partnering with a single vendor for comprehensive drug development, manufacturing, research, and clinical supply services can accelerate trial starts and substantially reduce development costs, according to new research by the Tufts Center for the Study of Drug Development.
The Evolution of Antibody Drug Discovery: Unlocking Innovation with Bioinformatics and Al
Since monoclonal antibodies (mAbs) were developed and received their first approval, they became indispensable as research tools and biotherapeutic agents.
Time to Get Level with Your Lab Balance or Analytical Lab Weighing
Analytical weighing plays a crucial role in daily laboratory practices. In basic research, it usually serves as the first step in preparing buffers, media, and reagents.
Sustainable Science Starts Here: Transform Your Lab with Eco-Friendly Practices
Learn how labs worldwide are reducing waste, cutting carbon emissions, and making smarter choices for a sustainable future.
Tech Transfer of a Biologic Upstream Process
This insightful article delves into the intricacies of transferring technology in the biopharmaceutical industry. It highlights the importance of a structured and modular approach to ensure flexibility, consistency, and agility in meeting market needs.
Unlock the Secrets to Successful Biopharmaceutical Tech Transfer
In the rapidly evolving world of biopharmaceuticals, the ability to efficiently transfer manufacturing processes is crucial for meeting clinical and commercial demands.
Outsourcing supply chain and buffer preparation activities
As the biopharmaceutical market evolves and continues a steep upward trajectory of growth, biopharmaceutical drug innovators increasingly rely on contract development and manufacturing organizations (CDMOs) to help them achieve their mission.
The Innovation Imperative: Pioneering New Modalities for Therapeutic Leadership
In the rapidly evolving landscape of pharmaceuticals and biotechnology, the emergence of multimodal drug discovery heralds a transformative era for drug discovery, where innovation and strategic Foresight are paramount.
From early innovations to commercial triumphs: One viral vector partner for every stage of gene therapy development
Viral vector-based gene therapies hold promise for treating previously untreatable diseases like genetic disorders, rare cancers, and infectious diseases.
